Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)

NCT06308653 is registered in ClinicalTrials.gov with Usona Institute as lead sponsor.

NCT NCT06308653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06308653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)
Lead sponsor
Usona Institute
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 13, 2024
Completion date
January 30, 2027
Enrollment
238 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major